CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation

Under the Medicare Drug Price Negotiation Program (“Negotiation Program”), CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. CMS announced that the […]

By: Marilyn Schultz

Under the Medicare Drug Price Negotiation Program (“Negotiation Program”), CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. CMS announced that the drug companies that manufacture the 15 drugs (PDF) payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiations in the Negotiation Program have chosen to participate in the Negotiation Program.

Read the full fact sheet.

< Previous All Blogs Next >

Connect with our Team

614-763-2255

You can also fill out this form and we will reach out to you as soon as possible!

By clicking the submit button, I expressly consent by electronic signature to receive communications by telephone, by email, or by text message from Cornerstone Senior Marketing at the telephone number above (even if my number is currently listed on any state, federal, local, or corporate Do Not Call list) including my wireless number if provided. Carrier message and data rates may apply. I understand that my consent is not required as a condition of purchasing any goods or services and that I may revoke my consent at any time. I also acknowledge that I have read and agree to the Privacy Policy and Terms & Conditions. If you do not want to share your information, please click on Do Not Sell My Information for more details.